Claims for Patent: 10,294,242

Summary for Patent: 10,294,242

Title:	Diaryl macrocycle polymorph
Abstract:	This disclosure relates to polymorphs of (7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one that are useful in the treatment of disease, such as cancer, in mammals. This disclosure also relates to compositions including such polymorphs, and to methods of using such compositions in the treatment of diseases, such as cancer, in mammals, especially in humans.
Inventor(s):	Cui Jingrong J., Rogers Evan W.
Assignee:	TP Therapeutics, Inc.
Application Number:	US15741893
Patent Claims:	2. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 9.4±0.1 claim 1 , 16.1±0.1 claim 1 , 16.5±0.1 claim 1 , 18.8±0.1 claim 1 , 21.2±0.1 claim 1 , 22.8±0.1 claim 1 , and 27.4±0.1.3. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 27.4±0.1 and 22.8±0.1.4. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 27.4±0.1 and 21.2±0.1.5. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 27.4±0.1 and 18.8±0.1.6. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 27.4±0.1 and 16.5±0.1.7. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 27.4±0.1 and 16.1±0.1.8. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 27.4±0.1 and 9.4±0.1.9. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 27.4±0.1 claim 1 , 22.8±0.1 claim 1 , and 21.2±0.1.10. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 27.4±0.1 claim 1 , 22.8±0.1 claim 1 , and 18.8±0.1.11. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 27.4±0.1 claim 1 , 22.8±0.1 claim 1 , and 16.5±0.1.12. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 27.4±0.1 claim 1 , 22.8±0.1 claim 1 , and 16.1±0.1.13. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 27.4±0.1 claim 1 , 22.8±0.1 claim 1 , and 9.4±0.1.14. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 27.4±0.1 claim 1 , 21.2±0.1 claim 1 , and 18.8±0.1.15. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 27.4±0.1 claim 1 , 21.2±0.1 claim 1 , and 16.5±0.1.16. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 27.4±0.1 claim 1 , 21.2±0.1 claim 1 , and 16.1±0.1.17. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 27.4±0.1 claim 1 , 21.2±0.1 claim 1 , and 9.4±0.1.18. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 27.4±0.1 claim 1 , 18.8±0.1 claim 1 , and 16.5±0.1.19. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 27.4±0.1 claim 1 , 18.8±0.1 claim 1 , and 16.1±0.1.20. The crystalline polymorph form of claim 1 , wherein the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 27.4±0.1 claim 1 , 18.8±0.1 claim 1 , and 9.4±0.1.